Back to top
more

Compugen (CGEN)

(Real Time Quote from BATS)

$1.64 USD

1.64
134,670

+0.01 (0.61%)

Updated Aug 8, 2024 09:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bayer's (BAYRY) AskBio Advances Parkinson Disease Study

by Zacks Equity Research

Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

by Zacks Equity Research

ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.

Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals

by Zacks Equity Research

Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.

Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?

by Zacks Equity Research

Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.

Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

by Zacks Equity Research

Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.

Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals

by Zacks Equity Research

Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals

by Zacks Equity Research

Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

by Zacks Equity Research

Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

by Zacks Equity Research

ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.

Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag

by Zacks Equity Research

Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.

Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals

by Zacks Equity Research

Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.

Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data

by Zacks Equity Research

Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.

Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Compugen (CGEN) delivered earnings and revenue surprises of 20% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice

by Zacks Equity Research

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

BOX Gears Up to Report Q4 Earnings: Here's What to Expect

by Zacks Equity Research

BOX's fourth-quarter fiscal 2024 results are likely to reflect gains from the growing adoption of content cloud solutions.

Will Petrobras (PBR) Report Q4 Earnings Beat on Output Gains?

by Zacks Equity Research

Petrobras (PBR) beat the Zacks Consensus Estimate in two of the last four quarters and missed in the other two, which resulted in an earnings surprise of 3.8%, on average.

Is a Surprise Coming for Compugen (CGEN) This Earnings Season?

by Zacks Equity Research

Compugen (CGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Baidu (BIDU) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Baidu's (BIDU) fourth-quarter results are likely to reflect the benefits of its AI business and growing autonomous driving efforts amid uncertainties in China.

Vipshop (VIPS) to Post Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Vipshop's (VIPS) fourth-quarter results are expected to reflect strength in its merchandising strategy and discount retail business amid macroeconomic challenges in China.

ACM Research (ACMR) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

ACM Research's (ACMR) fourth-quarter 2023 results are expected to reflect gains from semiconductor, ECP and advanced packaging businesses.

What to Look for in Crescent Point's (CPG) Q4 Earnings?

by Zacks Equity Research

Lower price realizations and an upward cost trajectory are likely to have dented Crescent Point Energy's (CPG) fourth-quarter results.

Agilent Technologies (A) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Agilent's (A) results for the fiscal first quarter are expected to reflect strength across ACG amid weakness in the LSAG and DGG segments.

What's in Store for Qurate Retail (QRTEA) in Q4 Earnings?

by Zacks Equity Research

Qurate Retail's (QRTEA) fourth-quarter 2023 results are likely to reflect strength in gardening, food and kitchen, and home decor categories.